Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have voluntarily signed a consent form to take part
• People with a general health status rated between 0 and 3 on the ECOG scale, which measures how much a condition affects daily activities (confirm with trial site)
• People with an expected survival of more than 3 months
• People who have had a laboratory-confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) that is found only in the brain, spinal cord, or eyes (known as Primary CNS Lymphoma, or PCNSL)
• People with a measurable area of disease visible on a contrast MRI scan (larger than 10x10 mm), or positive fluid test results indicating disease in the lining of the brain or spinal cord
• People who have not previously received systemic (whole-body) treatment for lymphoma, with the exception of steroid medications
• People whose blood counts and organ function meet specific levels for bone marrow, liver, and kidneys as determined by blood tests (confirm with trial site for exact values)
• People with stable, well-managed other health conditions, such as controlled high blood pressure, type 2 diabetes, or mild heart disease, provided certain health thresholds are met
• People who are able to communicate well enough to complete patient questionnaires, without severe cognitive impairment
• People of reproductive age who agree not to plan a pregnancy during the study and for 3 months after treatment ends, and who agree to use effective contraception throughout that period; male participants must also agree not to donate sperm during treatment and for 3 months after it ends
• For the observational palliative care group only: people with a laboratory-confirmed diagnosis of DLBCL restricted to the brain or eyes, and who are able to attend follow-up assessments

Who may not be able to join:

• People who have previously been treated with certain immune checkpoint therapies (PD-1, PD-L1, or CTLA-4 inhibitors)
• People with an active, uncontrolled infection
• People with serious or uncontrolled heart conditions, including severe heart failure, a heart attack or unstable chest pain within the past 6 months, heart rhythm problems requiring treatment, or a heart pumping function below 50%
• People with a primary disease of the heart muscle
• People with a history of significant abnormal heart rhythm readings on an ECG, certain types of heart conduction blocks, or current ECG readings above specific thresholds (confirm with trial site)
• People with poorly controlled atrial fibrillation (an irregular heartbeat) at a certain severity level
• People with high blood pressure that cannot be controlled with treatment
• People with active hepatitis B or C infection, or active syphilis (people with previously cured hepatitis C or hepatitis B that is not detectable may still be considered — confirm with trial site)
• People living with HIV
• People who have previously had an organ transplant or a bone marrow/stem cell transplant from a donor
• People who are pregnant or currently breastfeeding
• People with a current or past history of lung scarring conditions such as pulmonary fibrosis, interstitial lung disease, dust-related lung disease, or radiation-related lung damage
• People with autoimmune diseases that have required systemic (whole-body) treatment within the past 2 years
• For the observational palliative care group only: people whose medical records are incomplete, such as those without a pathology report or who are unable to undergo MRI or PET-CT scanning

Important: Always verify eligibility with the trial site directly before applying.